RETROPHIN, INC. RTRX Cash Flow

Retrophin, inc. (RTRX)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Nov'12	Sep'12	Aug'12	Jun'12	May'12	Mar'12	Feb'12	Nov'11	Aug'11	May'11
Cash Flows From Operating Activities:
Net income (loss)
-104,642	-146,427	-123,623	-141,649	-125,277	-102,678	-112,841	-76,119	-67,019	-59,731	-50,716	-70,035	-70,209	-47,903	-41,769	100,922	88,798	117,237	90,679	-32,879	4,452	-110,938	-94,503	-88,764	-105,491	-34,625	-22,036	-9,798	-4,879	-	-14	-	-14	-	-14	0	-14	0	0	0
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
21,163	20,408	19,997	19,419	19,221	18,668	18,257	18,074	17,868	17,804	17,518	16,998	16,528	16,135	15,928	15,714	15,504	13,392	11,275	9,244	7,052	5,401	3,599	1,803	291	216	210	192	176	124	-	0	-	0	-	0	-	-	-	-
Legal fee settlement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
(Accretion) amortization of discounts/premiums on investments, net
307	788	1,146	845	317	-382	-1,115	-1,383	-1,407	-1,338	978	1,161	1,199	1,097	-455	-268	9	398	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred income tax benefit
-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accretion of notes receivable
-	-	-	-	-	-	-	-	-	651	973	1,293	1,612	1,927	2,872	2,552	1,907	1,267	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of debt discount and issuance costs
9,995	9,903	9,815	8,006	5,857	3,398	0	0	0	-	-	-	-	656	656	656	1,001	1,340	1,688	2,090	1,586	1,084	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Realized (gain) loss on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,512	2,081	2,451	2,349	977	749	378	374	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Gain upon divestiture of assets to Turing Pharmaceuticals
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	914	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Settlement expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6,018	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Lease liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss on disposal of fixed assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for Inventory
1,699	1,468	186	1,721	1,830	2,457	0	0	0	-	-	-	-	-	-	-	-	1,050	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share based compensation
20,744	21,105	21,462	21,561	21,386	19,774	20,502	22,702	24,440	26,874	28,360	29,148	29,402	29,102	29,186	29,619	27,120	25,900	25,411	20,434	18,068	15,900	0	0	0	-	-	0	0	-	-	-	-	0	-	0	-	-	-	-
Change in fair value of contingent consideration
9,961	-2,948	-22,977	-5,674	-6,868	11,590	30,719	18,547	19,672	19,389	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Legal accrual reversal
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Compensation in lieu of receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	407	-	0	-	0	-	0	-	-	-	-
Share based compensation - non-employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	-	-	-
Bargain purchase gain
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	49,063	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability
0	-	0	0	0	-	0	0	16,058	-	0	0	0	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Inventory Reserve
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Write off of IPR&D intangible assets
0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments from change in fair value of contingent consideration
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,662	1,325	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Fair Value Adjustment of Warrants
-	-	-	-	-	-	-	-	-	-	-	-	11,425	-1,655	1,976	-38,141	-17,786	33,307	45,690	69,322	6,925	23,786	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other
138	51	366	535	409	396	262	81	61	83	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Share based payment - Technology license contingent fee
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,550	-	0	-	0	-	0	-	-	-	-
Change in estimated fair value of derivative financial instruments - warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	0	-	0	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable
5,285	5,184	5,183	3,675	694	-152	-2,227	-1,691	-2,755	-4,945	-518	-2,748	2,087	6,090	1,508	5,149	5,228	4,504	8,823	9,866	8,133	7,959	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Inventory
2,746	1,958	398	1,422	2,350	2,773	2,815	1,927	1,725	1,706	175	606	840	568	602	708	1,123	1,174	1,401	943	635	282	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Tax receivable
0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current and non-current operating assets
0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,106	966	433	-631	98	-237	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	-	0	-	0	-	-	-	-
Fair value of services provided by related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	0
Accounts payable and accrued expenses
0	-	0	0	0	-	0	0	0	-	0	0	8,606	-	7,829	7,446	1,925	3,379	5,668	10,641	16,920	20,604	14,764	9,075	7,169	2,842	4,145	3,201	338	2,978	-	675	-	90	0	-109	-	0	0	0
Other current and non-current operating liabilities
0	-	0	0	0	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income taxes payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-66,877	-58,214	-57,287	-47,065	-30,716	-24,958	-22,247	-12,150	-3,924	7,403	-236	-1,805	-3,281	-3,441	1,500	-2,390	1,638	-1,389	-6,932	-23,171	-42,638	-45,850	-45,151	-32,057	-22,816	-17,589	-9,192	-6,786	-4,578	-	0	-	-0	-	-0	0	-0	0	0	0
Cash Flows From Investing Activities:
Purchase of fixed assets
384	195	286	147	707	727	177	432	88	887	2,804	2,460	2,242	1,428	48	17	21	22	117	268	521	663	675	531	276	117	38	30	29	24	-	0	-	0	-	0	-	-	-	-
Cash paid for intangible assets
15,815	15,370	15,165	14,932	14,718	18,974	18,598	18,233	17,862	13,122	12,496	11,893	11,398	10,496	9,369	9,392	8,635	7,008	5,270	2,497	4,187	3,301	8,729	8,728	5,494	5,433	0	0	0	-	-	0	-	0	-	0	-	-	-	-
Investment - Equity
-	-	-	-	-	15,000	15,000	15,000	10,000	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from the sale/maturity of marketable securities
235,310	259,100	247,434	215,235	208,866	162,800	133,840	134,125	132,984	114,500	143,717	143,566	150,445	159,500	97,609	69,569	27,190	9,977	9,218	4,890	5,170	6,493	6,259	6,270	5,989	4,385	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Purchase of marketable securities
148,290	223,712	262,525	396,626	382,248	331,345	254,683	95,721	131,934	102,415	99,647	151,807	159,459	184,111	255,753	267,047	223,182	198,530	94,793	5,262	7,479	10,149	10,842	9,011	6,793	4,124	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Purchase of amortizable intangible asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-
Repayment of technology license liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,300	0	0	0	-	-	0	-	0	-	0	-	-	-	-
Proceeds from securities sold, not yet purchased
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7,500	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Cash received upon sale of assets, net
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	148,411	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Securities sold, not yet purchased
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Cash received upon divestiture of asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid upon acquisition, net of cash acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	33,430	33,430	33,430	33,430	29,150	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash received in merger transaction
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3	3	3	3	-	0	-	0	-	0	-	-	-	-
Payments made on behalf of affiliate
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	137	-	0	-	0	-	0	-	-	-	-
Loans made to stockholder
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Increase in note receivable - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-
Net cash provided by (used in) investing activities
70,826	19,863	-30,519	-196,529	-193,852	-203,291	-154,592	4,765	20,626	45,602	76,175	72,311	24,251	10,370	-120,561	-62,287	-59,548	-80,602	21,829	-32,456	-36,960	-37,263	-37,968	-41,260	-35,212	-5,406	-6,800	-1,735	-2,805	-1,699	-	0	-	0	-	0	-	-	-	-
Cash Flows From Financing Activities:
Payment of acquisition-related contingent consideration
7,791	3,388	3,441	3,496	3,560	9,721	7,935	8,792	10,097	4,099	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	0	-	-	-	-
Repayment of net amounts due to related parties
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Payment of other liability
-	-	-	-	-	-	-	-	-	852	0	0	0	-	-	-	-	2,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payment of guaranteed minimum royalty
2,100	2,084	2,059	2,034	2,009	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	2,000	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Note Purchase Agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	930	-	0	-	0	-	0	-	-	-	-
Proceeds from Issuance of Warrants
-	-	-	-	-	5,305	4,274	5,785	4,253	3,645	0	0	0	-	-	-	-	4,475	4,433	647	4,878	8,398	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
1,374	1,618	1,153	4,015	6,636	10,588	10,771	11,974	10,379	8,087	9,486	5,447	5,199	4,016	3,806	5,721	7,442	6,818	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Repayment of note payable - related party
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	885	914	930	930	45	-	0	-	0	-	0	-	-	-	-
Investors' deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	100	-	0	-	0	-	0	-	-	-	-
Repurchase of 2019 convertible senior notes including premium
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-
Proceeds received from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	149,487	152,619	152,619	149,454	40,000	36,666	58,496	61,661	30,937	31,815	10,706	12,210	3,475	-	0	-	0	-	0	-	-	-	-
Purchase of treasury stock, at cost
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,257	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Repayment of stock subscription receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	0	-	-	-	-
Net cash used in financing activities
-6,740	-2,077	-1,647	230,046	233,455	231,863	232,699	7,579	2,597	5,445	-960	-2,757	-2,777	-3,849	2,427	-41,722	-38,699	101,602	99,837	143,493	196,078	95,320	95,572	112,911	59,220	28,981	30,048	9,896	11,400	4,437	-	0	-	0	-	0	-	-	-	-
Effect of exchange rate changes on cash
-28	-9	-179	-100	-166	-135	-31	-155	-52	-58	117	362	415	117	-67	-192	-304	-10	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash and cash equivalents
-2,819	-40,437	-89,632	-13,648	8,721	3,479	55,829	39	19,247	58,392	75,096	68,111	18,608	3,197	-116,701	-106,591	-96,913	19,601	114,734	87,866	116,479	12,207	12,452	39,593	1,192	5,986	13,407	255	2,502	1	-	0	-	0	-	0	-	-	-	-
Financing costs from issuance of common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental Disclosure of Cash Flow Information:
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	28	33	43	43	14	-	0	-	0	-	0	-	-	-	-
Non-cash Investing and financing activities:
Reclassification of derivative liability to equity due to exercise of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	23,365	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Present value of contingent consideration payable to sellers of Asklepion Pharmaceuticals LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares issued in connection with Cholbam acquisition
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Present value of contingent consideration payable to sellers of Manchester Pharmaceuticals LLC
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Note payable entered into upon acquisition of Manchester Pharmaceuticals, LLC.
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	31,283	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on securities sold, not yet purchased
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-
Allocation of proceeds from issuance of common stock to registration payment obligation
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	0	-	-	-	-
Unrealized gain (loss) on marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-
Cost incurred related to debt financing not yet paid
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common stock for subscription receivable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Change in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-0	-	-0	-	-0	0	0	0